Federal contract award
75A50123C00010
THE SCOPE OF THE PROPOSED PROGRAM INCLUDES MANUFACTURE OF SABIN?S SUDAN EBOLAVIRUS VACCINE (BULK DRUG SUBSTANCE (BDS) AND FINAL DRUG PRODUCT (FDP)) TO PROVIDE DOSES THAT MAY BE USED IN THE EVENT OF AN OUTBREAK SCENARIO. THE PROPOSED EFFORT WILL UTILI
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN42 — HEALTH R&D SERVICES; HEALTH CARE - OTHER; APPLIED RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $163.1M |
| Current contract value | $163.1M |
| Potential contract value / ceiling | $240.9M |
| Start date | Dec 29, 2022 |
| Current end date | Sep 30, 2030 |
| Potential end date | Sep 30, 2030 |
| Latest award activity | May 11, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 14 of 14 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| May 11, 2026 | P00013 | $4.3M | THE PURPOSE OF THIS MODIFICATION IS TO 1. OPTION 7 (CLIN 0008): DECREASE THE VALUE FROM $6,888,289.01 BY $1,713,590.57 TO $5,174,698.44. 2. OPTION 10 (CLIN 0011): INCREASE THE VALUE FROM $1,554,748.99 BY $1,713,590.57 TO $3,268,339.56. 3. OPTION 4 |
| Jul 29, 2025 | P00012 | $38.7M | THE PURPOSE OF THIS MODIFICATION IS TO 1. EXERCISE OPTION PERIOD 2 CLIN 0003 WITH A PERIOD OF PERFORMANCE OF JULY 22, 2025, TO DECEMBER 28, 2032, IN THE AMOUNT OF $38,697,183.73. AS A RESULT OF THIS MODIFICATION: 1. FUNDING IN THE AMOUNT OF $3 |
| Jul 8, 2025 | P00011 | $1.6M | THE PURPOSE OF THIS MODIFICATION IS AS FOLLOWS: 1. CLIN 0008 (OPTION 7) THE TOTAL UNEXERCISED VALUE IS HEREBY DECREASED FROM $8,443,038.00 BY $1,554,748.99 TO $6,888,289.01 TO ACCOUNT FOR A DECREASE IN THE SCOPE OF WORK DUE TO THE SHORTER PERIOD OF |
| May 1, 2025 | P00010 | $13.1M | THE PURPOSE OF THIS MODIFICATION IS AS FOLLOWS: 1. CLIN 0001/ BASE: INCREASE THE FUNDING FROM $52,015,534.00 BY $4,695,621.32 TO $56,711,155.32 TO FACILITATE THE ONSHORING OF FILLED DOSE STORAGE, AS WELL AS SUPPORT PROCESS DEVELOPMENT STUDIES AIMED |
| Jan 10, 2025 | P00009 | $0 | THE PURPOSE OF THIS NO COST MODIFICATION IS TO DONATE 188 VIALS OF SUDV CLINICAL TRIAL MATERIAL FOR THREE NONCLINICAL STUDIES AS FOLLOWS: 1. CLIN 0001 (BASE PERIOD) - 188 VIALS TO BE DONATED IN ACCORDANCE WITH FAR 45.106 BROKEN DOWN AS FOLLOWS: A. |
| Dec 16, 2024 | P00008 | $17.1M | THE PURPOSE OF THIS MODIFICATION IS HEREBY AMENDED AS FOLLOWS: 1. CLIN 0001 (BASE PERIOD) IS HEREBY AMENDED AS FOLLOWS: A. AN ADDITIONAL $17,053,156 IN FUNDS ARE BEING ALLOCATED TO ALLOW TO CONTINUE THE MANUFACTURING PROCESS DEVELOPMENT OF CHAD3-SU |
| Oct 10, 2024 | P00007 | $0 | THE PURPOSE OF THIS NO COST MODIFICATION IS TO ADD AN AUDIT OF REITHERA SRL TO THE SCOPE OF CLIN 0005 AS FOLLOWS: 1. CLIN 0005 (OPTION 4) IS HEREBY AMENDED AS FOLLOWS: A. THE STATEMENT OF WORK IS HEREBY AMENDED TO REFLECT AN ONSITE AUDIT OF REITHER |
| Sep 25, 2024 | P00006 | $17.0M | THE PURPOSE OF THIS MODIFICATION IS TO CHANGE PRODUCTION UNDER CLIN 0005 AND CLIN 0006 AND EXTEND THE PERIOD OF PERFORMANCE ON CLIN 0005 AS FOLLOWS: 1. CLIN 0005 (OPTION 4) IS HEREBY AMENDED AS FOLLOWS: A. ADDITIONAL PRODUCT DEVELOPMENT EFFORTS ARE |
| Aug 23, 2024 | P00005 | $0 | THE PURPOSE OF THIS NO COST MODIFICATION IS TO INCORPORATE AN UPDATED STATEMENT OF WORK AMENDING THE VERBIAGE AS FOLLOWS: 1. CLIN 0001 IS HEREBY AMENDED PERFORM ACTIVITIES TO FILL-FINISH 2L OF SUDV DRUG PRODUCT AND DONATE THAT MATERIAL TO THE SABIN |
| Jul 16, 2024 | P00004 | $0 | THE PURPOSE OF THIS $0 MODIFICATION IS TO: 1. CLIN 0001 IS HEREBY AMENDED TO INCLUDE AN ADDITIONAL 4TH DS BATCH RUN OF SUDV, AND TO REFLECT THE INCREASE OF REITHERA?S SUBCONTRACT BY $585,000 AT NO ADDITIONAL COST TO THE GOVERNMENT. 2. THIS REVISED |
| May 16, 2024 | P00003 | $0 | THE SCOPE OF THE PROPOSED PROGRAM INCLUDES MANUFACTURE OF SABIN?S SUDAN EBOLAVIRUS VACCINE (BULK DRUG SUBSTANCE (BDS) AND FINAL DRUG PRODUCT (FDP)) TO PROVIDE DOSES THAT MAY BE USED IN THE EVENT OF AN OUTBREAK SCENARIO. THE PROPOSED EFFORT WILL UTILI |
| Sep 8, 2023 | P00002 | $0 | THE SCOPE OF THE PROPOSED PROGRAM INCLUDES MANUFACTURE OF SABIN?S SUDAN EBOLAVIRUS VACCINE (BULK DRUG SUBSTANCE (BDS) AND FINAL DRUG PRODUCT (FDP)) TO PROVIDE DOSES THAT MAY BE USED IN THE EVENT OF AN OUTBREAK SCENARIO. THE PROPOSED EFFORT WILL UTILI |
| Aug 2, 2023 | P00001 | $36.4M | THE SCOPE OF THE PROPOSED PROGRAM INCLUDES MANUFACTURE OF SABIN?S SUDAN EBOLAVIRUS VACCINE (BULK DRUG SUBSTANCE (BDS) AND FINAL DRUG PRODUCT (FDP)) TO PROVIDE DOSES THAT MAY BE USED IN THE EVENT OF AN OUTBREAK SCENARIO. THE PROPOSED EFFORT WILL UTILI |
| Dec 29, 2022 | 0 | $35.0M | THE SCOPE OF THE PROPOSED PROGRAM INCLUDES MANUFACTURE OF SABIN?S SUDAN EBOLAVIRUS VACCINE (BULK DRUG SUBSTANCE (BDS) AND FINAL DRUG PRODUCT (FDP)) TO PROVIDE DOSES THAT MAY BE USED IN THE EVENT OF AN OUTBREAK SCENARIO. THE PROPOSED EFFORT WILL UTILI |
Estimated positioning window
Sep 30, 2029 – Mar 30, 2030
Recompete signal: . Rule-based research score; positioning dates are estimates.
50/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 50/100. Available recorded signals: 45 points.
- Contract end 2030-09-30 (1429 days from calculation)
- +5 points
- 22 historical awards in this buyer and category group
- +15 points
- 14 recorded award transactions
- +10 points
- Latest award action: 2026-05-11
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-11-01 10:17:53.997580+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Nov 1, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.